研报掘金丨中金:和黄医药赛沃替尼海外申报现曙光,目标价升至26港元

格隆汇
Aug 19
中金发表报告指,和黄医药公告赛沃替尼(沃瑞沙,Orpathys)联合阿斯利康的三代EGFR TKI奥希替尼(泰瑞沙,Tagrisso)全球三期注册临床SAFFRON积极结果,在奥希替尼治疗后进展的MET驱动EGFR突变肺癌中达到具有统计学和临床意义的无进展生存期(PFS)和总生存期(OS)改善。中金认为,SAFFRON试验PFS和OS均取得积极结果,对赛沃替尼海外申报具有关键意义,有力支撑赛沃替尼在美国等海外核心市场的申报。赛沃替尼联用奥希替尼疗法若获批,未来具备可行的商业路径和可观的市场空间。该行基本维持和黄医药今明两年归母净利润预测5555万美元及8865万美元不变,维持“跑赢行业”评级,根据DCF模型上调目标价9.24%至26港元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10